Table 2.
Common adverse effects of secukinumab treatment
| Clinical studies | Most common adverse effects (% of total patients on secukinumab regimen during entire trial) |
|---|---|
| Langley et al23 (FIXTURE study) | Nasopharyngitis (24.6%) |
| Headache (11.2%) | |
| Diarrhea (7.9%) | |
| McInnes et al28 | Nasopharyngitis (25.0%) |
| Headache (21.4%) | |
| Neutropenia (21.4%) | |
| Nausea (14.3%) | |
| Dizziness (14.3%) | |
| Rich et al21 | Nasopharyngitis (16.1%) |
| Neutropenia (6.3%) | |
| Headache (5.9%) | |
| Upper respiratory tract infection (4.2%) | |
| Papp et al20 | Nasopharyngitis (12.6%) |
| Neutropenia (7.4%) | |
| Headache (4.9%) | |
| Pharyngitis (2.9%) | |
| Ohtsuki et al25 | Nasopharyngitis (33.7%) |